Yipinhong pharmaceutical unveils share buyback plan to boost value

Yipinhong Pharmaceutical Group Co., Ltd. (SZSE:300723) announced on December 16, 2025, a plan to repurchase its A-share ordinary shares using self-owned and/or self-raised funds. The buyback, approved by the board on December 15, 2025, aims to protect company value and shareholder interests, with a total value not less than RMB 100m and not exceeding RMB 200m. The repurchase price will not exceed RMB 70.00 per share, and the program is scheduled to be completed within three months from the board's approval date.

The company's stock has experienced a cumulative decline of over 20% in its closing price over twenty consecutive trading days between November 14 and December 15, 2025. This meets the criteria for share repurchase under the Shenzhen Stock Exchange's Self-Regulatory Guidance No. 9 (2025 Revision). The board of directors and senior management, as well as the controlling shareholder, its actual controllers, and their concerted parties, have not engaged in any buying or selling of the company's shares in the six months prior to the board's resolution.

As of December 15, 2025, Guangdong Guangrun Group Co., Ltd. remains the largest shareholder with 183.6m shares, representing 40.65% of the total share capital. The company has established a dedicated securities account for the repurchase and will regularly disclose progress according to regulatory requirements.